drugset / Trial / NCT03229265

Pharmacokinetic Study of Tacrolimus and Mycophenolate Mofetil in Kidney Transplant Recipients With Hyperkalemia Receiving Patiromer

NCT03229265

NaSingle-groupOpen-labelTreatment

Summary

Hyperkalemia (high potassium in blood) is a common condition found in kidney transplant patients. Risk factors include poor kidney function and exposure to various drugs. Regardless of the causes, current treatment options are limited. Previously, the only available potassium binder for lowering potassium in the blood is sodium polystyrene sulfonate, which has unknown drug interaction profile with transplant medications. Patiromer is a newly approved potassium binder indicated for the treatment of hyperkalemia. Kidney transplant patients with hyperkalemia may benefit from patiromer. However, the interaction of patiromer and transplant medications has not been studied. The goal of this study is to look into the drug interactions between patiromer and transplant medications.

Timeline

Start
2017-08-01
Primary completion
2019-08-07
Completion
2019-08-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Patiromer Other / unclassified 8.4 g

Indications

No indication recorded.